Novo Nordisk announces changes in Executive Management
Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual…
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to…
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions…
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings…
Novo Nordisk A/S – share repurchase programme
Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated…
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 November 2024 – This company announcement discloses the data…